Expression profile of angiogenic factors in paired initial and recurrent glioblastoma.

Authors

null

Emeline Tabouret

Aix-Marseille University, AP-HM, Service de Neuro-Oncologie, CHU Timone, Marseille, France

Emeline Tabouret , Aurelie Tchoghandjian , Emilie Denicolai , Christine Delfino , Philippe Metellus , Laetitia Padovani , Isabelle Nanni , Maryline Barrie , Celine Boucard , L'houcine Ouafik , Dominique Figarella-Branger , Olivier L. Chinot

Organizations

Aix-Marseille University, AP-HM, Service de Neuro-Oncologie, CHU Timone, Marseille, France, Aix-Marseille University, Marseille, France, Timone University Hospital, Marseille, France, Aix-Marseille University, AP-HM, Service de Neuro-Chirurgie, CHU Timone, Marseille, France, APHM, Service de Radiotherapy, Marseille, France, Laboratoire de transfert biologique, Aix Marseille University, Marseille, France, AP-HM, Service de Neuro-Oncologie, CHU Timone, Marseille, France, Aix-Marseille University, AP-HM, Service d'Anatomopathologie et de Neuropathologie, CHU Timone, Marseille, France

Research Funding

No funding sources reported

Background: Angiogenesis is one of the key features of Glioblastoma (GB). Our objective was to identify the changes in the expression of angiogenic factors in GB after radio-chemotherapy. Methods: Analysis of all patients with available frozen tumor material from initial and recurrent surgery for GB treated with chemo-radiotherapy (CTRT) in first line setting in our institution between 2003 and 2009. Molecular screening was realized using two types of RT²Profiler PCR arrays (Qiagen). The RNA expression profile of selected genes was validated using quantitative RT PCR. Protein expression was analyzed by immunohistochemistry (IHC). Explants of newly GB were treated with temozolomide, radiotherapy and anti-CXCR4 (AMD3100). Results: Twenty nine patients were included with median age of 57.1 years (37.2-74.1). The RT2Profiler PCR arrays results allowed a selection of seven genes: VEGFA, VEGFR2, VEGFR1, Adrenomedullin, SDF1, CXCR4, and HIF1α. The steady state levels of CXCR4 RNA at recurrence was significantly increased (p=0.029) while HIF1α RNA was significantly decreased (p=0.009). A trend for a decrease of VEGFR2 RNA (p=0.081) and an increase of SDF1 RNA (p=0.107) was observed. Changes of SDF1 RNA tended to be correlated to changes of CXCR4 RNA (p=0.077) and inversely correlated to changes of HIF1 α RNA (p=0.064). By IHC, VEGFR2 staining was significantly decreased at recurrence (p=0.004) while SDF1 expression tended to increased (p=.096). Medians initial and at recurrence overall survival (OSI and OSR) of this selected population were 25.5 (95% confidence interval (CI) 17-34) and 11.4 (95%CI 9-13.9) months respectively. By multivariate analysis, VEGFR2 RNA initial and at recurrence levels were significantly correlated to OSI (p=0.019, Hazard ratio (HR) =3.650) and OSR (p=0.024, HR=2.536) while HIF1 α RNA level at baseline was correlated to OSI (p=0.012, HR=0.300). In newly GB explants, a higher anti-tumoral effect was observed with the combination of AMD3100 and CTRT versus CTRT alone. Conclusions: Acquired resistance of GB to chemo-radiation could be associated with a switch of angiogenic pattern from VEGFR2-HIF1α to SDF1-CXCR4 pathway, leading to new perspectives in angiogenic modulation and GB treatment.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2014 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Central Nervous System Tumors

Track

Central Nervous System Tumors

Sub Track

Central Nervous System Tumors

Citation

J Clin Oncol 32:5s, 2014 (suppl; abstr 2060)

DOI

10.1200/jco.2014.32.15_suppl.2060

Abstract #

2060

Poster Bd #

25

Abstract Disclosures

Similar Abstracts

First Author: Joshua Nahm

First Author: Benjamin Joshua Lerman

First Author: Emilie Le Rhun